- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.11. | Institute of BioMedical Research Corp.: MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer at M2Bio Sciences | 157 | ACCESSWIRE | DUBAI, UAE / ACCESSWIRE / November 25, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), operating as M2Bio Sciences, is a pioneering biotechnology company dedicated to advancing health... ► Artikel lesen | |
| 22.08. | Institute of BioMedical Research Corp.: MRES: M2Bio Food and Beverage Refocuses Strategy: Expanding Beyond CBD to Reach Global Consumers | 267 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 22, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), a pioneering nutraceutical biotechnology company that delves into the innovative... ► Artikel lesen | |
| 22.03. | Institute of BioMedical Research Corp.: MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead | 562 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specialising in alternative... ► Artikel lesen | |
| 01.03. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Provides Corporate Update | 400 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation... ► Artikel lesen | |
| INSTITUTE OF BIOMEDICAL RESEARCH Aktie jetzt für 0€ handeln | |||||
| 23.02. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development | 646 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
| 22.02. | Institute of BioMedical Research Corp.: MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward | 747 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative... ► Artikel lesen | |
| 09.02. | Institute of BioMedical Research Corp.: MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward | 497 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
| 02.01. | Institute of BioMedical Research Corp.: MRES: M2MMA Gears Up for a Landmark Year in 2024 | 1.025 | ACCESSWIRE | CAPE TOWN / ACCESSWIRE / January 2, 2024 / CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / January 2, 2024 / Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NEUROCRINE BIOSCIENCES | 139,03 | 0,00 % | Neurocrine Announces Commercial Launch Of Crenessity In US | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal... ► Artikel lesen | |
| AMGEN | 263,24 | -0,47 % | Spotlight on Amgen: Analyzing the Surge in Options Activity | ||
| BIOGEN | 149,90 | 0,00 % | BMO cuts rating on Merck and Biogen, on lack of near term catalyst | ||
| IDEXX LABORATORIES | 417,11 | 0,00 % | Jim Cramer on IDEXX Laboratories (IDXX): Is This Pet Stock Poised for a Comeback? | ||
| REGENERON PHARMACEUTICALS | 716,74 | +0,32 % | Regeneron Pharma: Phase 3 Trial With EYLEA HD 8 Mg Meets Primary Endpoint | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or aflibercept injection 8 mg... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 123,37 | +1,21 % | Sarepta awarded $115.2M in Vyondys 53 patent case: report | ||
| MODERNA | 40,440 | 0,00 % | Moderna-Deutschland-Chef im Interview (2): "Onkologie ist ein bedeutendes Forschungsfeld für ... | Die Aktie von Moderna hat sich in den vergangenen Monaten alles andere als erfreulich entwickelt. Im Mai notierte das Papier noch über 170 Dollar. Mittlerweile steht seitdem ein Kursverlust von 77 Prozent... ► Artikel lesen | |
| QUANTUM-SI | 2,150 | 0,00 % | Quantum-Si präsentiert ProteoVue-Software für Proteinforschung | ||
| VAXCYTE | 85,78 | 0,00 % | Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset | ||
| GERON | 3,300 | 0,00 % | Geron Gets Positive CHMP Opinion For RYTELO In Transfusion-Dependent Anemia Due To Lower-Risk MDS | WASHINGTON (dpa-AFX) - Geron Corporation (GERN), a commercial-stage biopharmaceutical company, Friday said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,660 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 48,030 | +1,03 % | Evotec: COO-Abgang und Halozyme-Übernahmepläne | Dr. Craig Johnstone, COO von Evotec, verlässt das Unternehmen nach zwölf Jahren, während ein internes Team vorübergehend seine Aufgaben übernimmt. Parallel brodelt die Gerüchteküche um eine mögliche... ► Artikel lesen | |
| TEMPUS AI | 35,230 | 0,00 % | Tempus AI (NASDAQ:TEM) Shares Down 5.7% Following Insider Selling | ||
| GUARDANT HEALTH | 31,370 | 0,00 % | Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance | PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024.
Third Quarter... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 7,600 | 0,00 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering... ► Artikel lesen |
INSTITUTE OF BIOMEDICAL RESEARCH CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INSTITUTE OF BIOMEDICAL RESEARCH CORP finden Sie auf Wallstreet Online.
